Last May, HIPRA organized the launch of HIPRABOVIS® SOMNI/Lkt (vaccine against pneumonia caused by Histophilus somni and Mannheimia haemolytica leukotoxoid) and HIPRABOVIS® BALANCE (vaccine against PI3, BVD and BRS viruses) in Medellín, Colombia.

Over 40 professionals from the Colombian cattle production industry attended the event, including veterinarians, producers and breeders. During the session, HIPRA presented the new combination of these two innovative vaccines that had recently been registered in Colombia.

At this event, Dr Ramón Armengol, Associate Professor at Lleida University, gave a presentation entitled “Early diagnosis and management of bovine respiratory disease (BRD) in replacement heifers: from birth to first calving" so that he could share with the audience his experience in terms of BRD diagnosis and management in dairy heifers.

Antonio Souto (Regional Technical Marketing Manager South America) then presented HIPRABOVIS® SOMNI/Lkt, a vaccine that provides protection against 2 pasteurella species), reducing clinical signs by 50%, lung lesions by 50% and antibiotic use five-fold.

In addition, Vincent Robles (Reproductive Ruminants Brand Manager) presented to the audience the global solution proposed by HIPRA for the control of 3 important viruses (BVD, BRSV, PI3) -which not only cause BRD but also reproductive disorders- a compound of the trivalent vaccine HIPRABOVIS®BALANCE and of an innovative diagnostic tool, BOVIRESPcheck, to identify viruses by PCR.

This new landmark positions HIPRA as the first global pharmaceutical company to offer its customers in Colombia a global approach to respiratory diseases in cattle.